Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Sally Suliman
Associate Professor, Internal Medicine (Clinical Scholar)
COM - Phoenix Internal Medicine
Overview
Research
More
Collaboration
(7)
Sally Voss
Mutual work: 2 Grants
Collaboration Details
Susan Sheerin-Fadden
Mutual work: 2 Grants
Collaboration Details
Elena Young
Mutual work: 2 Grants
Collaboration Details
Arianna Bedoya
Mutual work: 1 Grant
Collaboration Details
Mason Burchfield
Mutual work: 2 Grants
Collaboration Details
Page 1 of 2
Previous page
Next page
Grants
(5)
A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALT-100 in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)
Active
·
2023
·
$0 / $369.2K
·
External
undefined (CD)
respiratory diseases,
drug efficacy,
clinical trials,
patient safety,
medical treatment
A Randomized, Doubleblind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Active
·
2023
·
$1M / $167.3K
·
External
Principal Investigator (PI)
pulmonary fibrosis,
inhaled treprostinil,
efficacy,
safety
A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
2022
·
$2.2M
·
External
Principal Investigator (PI)
drug safety,
pulmonary fibrosis,
long-term efficacy,
prm-151
A Phase III Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis
2021
·
$570K
·
External
Principal Investigator (PI)
pulmonary fibrosis,
clinical trial,
drug efficacy,
safety assessment
A Randomized, Double-blind Dose-ranging, Placebo-controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (IPF)..
2021
·
$119.3K
·
External
Principal Investigator (PI)
drug evaluation,
pulmonary fibrosis,
pharmacokinetics,
safety and tolerability